Rajani Kanteti

Enteropathogenic Escherichia coli EspG disrupts microtubules and in conjunction with Orf3 enhances perturbation of the tight junction barrier.

Balance of bacterial pro- and anti-inflammatory mediators dictates net effect of enteropathogenic Escherichia coli on intestinal epithelial cells.

Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion.

PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription.

The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.

Enterohemorrhagic Escherichia coli suppresses inflammatory response to cytokines and its own toxin.

Ethnic differences and functional analysis of MET mutations in lung cancer.

MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance.

CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.

EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation.

Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions.

Role of protein kinase C β and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism.

RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.

Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database.

Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer.